Literature DB >> 21764662

Higher efficacy of pre-hospital tirofiban with longer pre-treatment time to primary PCI: protection for the negative impact of time delay.

Ton Heestermans1, Menko-Jan de Boer, Jochem W van Werkum, Arend Mosterd, A T Marcel Gosselink, Jan-Henk E Dambrink, Gert van Houwelingen, Petra Koopmans, Christian Hamm, Felix Zijlstra, Jurriën M ten Berg, Arnoud W J van 't Hof.   

Abstract

AIMS: To evaluate the impact of longer duration of pre-hospital initiated antiplatelet and antithrombotic therapy on outcome in patients with ST-segment elevation myocardial infarction (STEMI). METHODS AND
RESULTS: In this sub-analysis of the Ongoing Tirofiban in Myocardial Evaluation (On-TIME) 2 trial, we studied, in 1,370 patients, the effect of pre-treatment time (time from administering study medication to time of angiography) on complete ST-segment resolution (STR), initial patency and 30-day mortality. Study medication consisted of high dose tirofiban (HDT) or control (placebo or no HDT) on top of high dose clopidogrel, aspirin and unfractionated heparin. Median pre-treatment time was 55 min (44-70). Longer pre-treatment was associated with longer transportation times, longer in-hospital delay, longer total ischaemic time (all p<0.001) and higher 30-day mortality (3.6% vs. 1.8%, p=0.046). Longer HDT pre-treatment time was independently associated with increased complete STR both before (odds ratio [OR] 1.51, 95%; confidence interval [CI] 0.98-2.32; p=0.06) and after PCI (OR 1.43, 95%; CI 1.02-2.02; p=0.039) and with a significantly improved initial TIMI 2 or 3 flow (51.4% vs. 43.4%, p=0.042) and reduced 30-day mortality (2.1% vs. 5.0%, p=0.047) as compared to longer control pre-treatment.
CONCLUSIONS: Longer time delay before primary PCI is associated with increased mortality. Pre-treatment with high dose tirofiban, however, may compensate for this negative effect by improving ST-segment resolution and initial patency and by reducing mortality. Further studies should be performed to confirm that this is an attractive therapy for patients with longer delays to reperfusion.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21764662     DOI: 10.4244/EIJV7I4A73

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  6 in total

Review 1.  Platelet GP IIb-IIIa Receptor Antagonists in Primary Angioplasty: Back to the Future.

Authors:  Giuseppe De Luca; Stefano Savonitto; Arnoud W J van't Hof; Harry Suryapranata
Journal:  Drugs       Date:  2015-07       Impact factor: 9.546

2.  Impact of TIMI 3 patency before primary percutaneous coronary intervention for ST-elevation myocardial infarction on clinical outcome: results from the ASSENT-4 PCI study.

Authors:  Uwe Zeymer; Kurt Huber; Yuling Fu; Allan Ross; Christopher Granger; Patrick Goldstein; Frans van de Werf; Paul Armstrong
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2012-06

3.  Reperfusion delay in patients treated with primary percutaneous coronary intervention: insight from a real world Danish ST-segment elevation myocardial infarction population in the era of telemedicine.

Authors:  Mikkel M Schoos; Maria Sejersten; Anders Hvelplund; Mette Madsen; Jacob Lønborg; Jacob Steinmetz; Philip M Treschow; Frants Pedersen; Erik Jørgensen; Peer Grande; Henning Kelbæk; Peter Clemmensen
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2012-09

4.  Reducing system delays in treatment of ST elevation myocardial infarction and confronting the challenges of late presentation in low and middle-income countries.

Authors:  Sameer Mehta; Christopher B Granger; Timothy D Henry; Cindy Lee Grines; Alexandra Lansky; Ivan Rokos; Roberto Botelho; Andreas Baumbach; Sundeep Mishra; Tan Huay Cheem; Damras Tresukosol; Robaayah Zambahari; Alexandra Ferré; Marco Castillo
Journal:  Indian Heart J       Date:  2017-01-10

5.  Frequency of Thrombolysis in Myocardial Infarction III Flow in Patients With Primary Percutaneous Coronary Intervention: Not All Culprit Vessels Are Completely Occluded in ST Elevation Myocardial Infarction.

Authors:  Muhammad Hussain; Rajesh Kumar; Ali Ammar; Syed Alishan; Atif S Muhammad; Fawad Farooq; Tahir Saghir; Naveedullah Khan; Syed N Hassan Rizvi; Tariq Ashraf
Journal:  Cureus       Date:  2020-12-12

Review 6.  Pharmacokinetic, pharmacodynamic, and pharmacogenetic assays to monitor clopidogrel therapy.

Authors:  Bhawani Yasassri Alvitigala; Lallindra Viranjan Gooneratne; Godwin Roger Constantine; Rajapaksha Arachchige Namal Kumarasiri Wijesinghe; Liyanage Dona Ashanthi Menuka Arawwawala
Journal:  Pharmacol Res Perspect       Date:  2020-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.